Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1998 Dec 15;336(Pt 3):727–733. doi: 10.1042/bj3360727

Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.

M Aoyama 1, D R Grabowski 1, G R Dubyak 1, A I Constantinou 1, L A Rybicki 1, R M Bukowski 1, M K Ganapathi 1, I D Hickson 1, R Ganapathi 1
PMCID: PMC1219926  PMID: 9841887

Abstract

Topoisomerase II (topo II), an essential enzyme for cell viability, is also the target for clinically important anti-neoplastic agents that stimulate topo II-mediated DNA scission. The role of alterations in topo IIalpha phosphorylation and its effect on drug-induced DNA damage and cytotoxicity were investigated. Following loading of HL-60 cells with the calcium buffer 1, 2-bis-(o-aminophenoxy)ethane-N,N,N',N'-tetra-acetic acid tetra(acetoxymethyl) ester (BAPTA-AM), which abrogates intracellular Ca2+ transients, a significant decrease in etoposide (VP-16)- or amsacrine (m-AMSA)-stabilized topo II-DNA cleavable complex formation and a corresponding decrease in cytotoxicity was observed. In a cell-free system, nuclear extracts from BAPTA-AM-treated cells exhibited markedly less activity when assayed for VP-16-stabilized topo II-DNA complex formation, but not decatenation of kinetoplast DNA. In contrast, the loading of HL-60 cells with N,N,N', N'-tetrakis-(2-pyridyl)ethylenediamine (TPEN), which binds heavy metals without disturbing calcium or magnesium concentrations, did not significantly affect VP-16-stimulated topo II-DNA cleavable complex formation or cytotoxicity. In HL-60 cells the accumulation of BAPTA, but not TPEN, also led to the hypophosphorylation of topo IIalpha. Tryptic phosphopeptide mapping of topo IIalpha protein from HL-60 cells revealed: (a) eight major phosphorylation sites in untreated cells; (b) hypophosphorylation of two out of eight sites in BAPTA-AM-treated cells; and (c) hypophosphorylation of between two and four out of eight sites in topo II-poison-resistant HL-60 cells. The two hypophosphorylated sites present following BAPTA-AM treatment of wild-type cells were identical with the hypophosphorylated sites in the resistant cells, but were not the same as the sites that are substrates for casein kinase II [Wells, Addison, Fry, Ganapathi and Hickson (1994) J. Biol. Chem. 269, 29746-29751]. In summary, changes in intracellular Ca2+ transients that lead to the site-specific hypophosphorylation of topo IIalpha are possibly involved in regulating the DNA damage caused by and the cytotoxic potential of topo II poisons.

Full Text

The Full Text of this article is available as a PDF (161.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyle W. J., van der Geer P., Hunter T. Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol. 1991;201:110–149. doi: 10.1016/0076-6879(91)01013-r. [DOI] [PubMed] [Google Scholar]
  2. Chen A. Y., Liu L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994;34:191–218. doi: 10.1146/annurev.pa.34.040194.001203. [DOI] [PubMed] [Google Scholar]
  3. Darkin S. J., Ralph R. K. A protein factor that enhances amsacrine-mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei. Biochim Biophys Acta. 1989 Apr 12;1007(3):295–300. doi: 10.1016/0167-4781(89)90151-6. [DOI] [PubMed] [Google Scholar]
  4. Dubyak G. R., Cowen D. S., Meuller L. M. Activation of inositol phospholipid breakdown in HL60 cells by P2-purinergic receptors for extracellular ATP. Evidence for mediation by both pertussis toxin-sensitive and pertussis toxin-insensitive mechanisms. J Biol Chem. 1988 Dec 5;263(34):18108–18117. [PubMed] [Google Scholar]
  5. Ganapathi R., Constantinou A., Kamath N., Dubyak G., Grabowski D., Krivacic K. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Mol Pharmacol. 1996 Aug;50(2):243–248. [PubMed] [Google Scholar]
  6. Ganapathi R., Grabowski D., Ford J., Heiss C., Kerrigan D., Pommier Y. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Cancer Commun. 1989;1(4):217–224. [PubMed] [Google Scholar]
  7. Ganapathi R., Kamath N., Constantinou A., Grabowski D., Ford J., Anderson A. Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cells. Biochem Pharmacol. 1991 Jun 15;41(12):R21–R26. doi: 10.1016/0006-2952(91)90115-l. [DOI] [PubMed] [Google Scholar]
  8. Ganapathi R., Zwelling L., Constantinou A., Ford J., Grabowski D. Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells. Biochem Biophys Res Commun. 1993 May 14;192(3):1274–1280. doi: 10.1006/bbrc.1993.1554. [DOI] [PubMed] [Google Scholar]
  9. Grabowski D. R., Dubyak G. R., Rybicki L., Hidaka H., Ganapathi R. Tumor cell resistance to topoisomerase II poisons: role for intracellular free calcium in the sensitization by inhibitors or calcium-calmodulin-dependent enzymes. Biochem Pharmacol. 1998 Aug 1;56(3):345–349. doi: 10.1016/s0006-2952(98)00159-2. [DOI] [PubMed] [Google Scholar]
  10. Gromova I. I., Thomsen B., Razin S. V. Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei. Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):102–106. doi: 10.1073/pnas.92.1.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heck M. M., Hittelman W. N., Earnshaw W. C. In vivo phosphorylation of the 170-kDa form of eukaryotic DNA topoisomerase II. Cell cycle analysis. J Biol Chem. 1989 Sep 15;264(26):15161–15164. [PubMed] [Google Scholar]
  12. Hsiang Y. H., Liu L. F. Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J Biol Chem. 1989 Jun 15;264(17):9713–9715. [PubMed] [Google Scholar]
  13. Kao J. P., Alderton J. M., Tsien R. Y., Steinhardt R. A. Active involvement of Ca2+ in mitotic progression of Swiss 3T3 fibroblasts. J Cell Biol. 1990 Jul;111(1):183–196. doi: 10.1083/jcb.111.1.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kimura K., Saijo M., Tanaka M., Enomoto T. Phosphorylation-independent stimulation of DNA topoisomerase II alpha activity. J Biol Chem. 1996 May 3;271(18):10990–10995. doi: 10.1074/jbc.271.18.10990. [DOI] [PubMed] [Google Scholar]
  15. Meyer K. N., Kjeldsen E., Straub T., Knudsen B. R., Hickson I. D., Kikuchi A., Kreipe H., Boege F. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol. 1997 Feb 24;136(4):775–788. doi: 10.1083/jcb.136.4.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Redwood C., Davies S. L., Wells N. J., Fry A. M., Hickson I. D. Casein kinase II stabilizes the activity of human topoisomerase IIalpha in a phosphorylation-independent manner. J Biol Chem. 1998 Feb 6;273(6):3635–3642. doi: 10.1074/jbc.273.6.3635. [DOI] [PubMed] [Google Scholar]
  17. Ritke M. K., Allan W. P., Fattman C., Gunduz N. N., Yalowich J. C. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol. 1994 Jul;46(1):58–66. [PubMed] [Google Scholar]
  18. Ritke M. K., Roberts D., Allan W. P., Raymond J., Bergoltz V. V., Yalowich J. C. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br J Cancer. 1994 Apr;69(4):687–697. doi: 10.1038/bjc.1994.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sinha B. K., Eliot H. M. Etoposide-induced DNA damage in human tumor cells: requirement for cellular activating factors. Biochim Biophys Acta. 1991 Sep 23;1097(2):111–116. doi: 10.1016/0925-4439(91)90093-o. [DOI] [PubMed] [Google Scholar]
  20. Tsien R. Y. New calcium indicators and buffers with high selectivity against magnesium and protons: design, synthesis, and properties of prototype structures. Biochemistry. 1980 May 27;19(11):2396–2404. doi: 10.1021/bi00552a018. [DOI] [PubMed] [Google Scholar]
  21. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 1996;65:635–692. doi: 10.1146/annurev.bi.65.070196.003223. [DOI] [PubMed] [Google Scholar]
  22. Watt P. M., Hickson I. D. Structure and function of type II DNA topoisomerases. Biochem J. 1994 Nov 1;303(Pt 3):681–695. doi: 10.1042/bj3030681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wells N. J., Addison C. M., Fry A. M., Ganapathi R., Hickson I. D. Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase II in vitro. J Biol Chem. 1994 Nov 25;269(47):29746–29751. [PubMed] [Google Scholar]
  24. Wells N. J., Hickson I. D. Human topoisomerase II alpha is phosphorylated in a cell-cycle phase-dependent manner by a proline-directed kinase. Eur J Biochem. 1995 Jul 15;231(2):491–497. doi: 10.1111/j.1432-1033.1995.tb20723.x. [DOI] [PubMed] [Google Scholar]
  25. Zwelling L. A., Hinds M., Chan D., Mayes J., Sie K. L., Parker E., Silberman L., Radcliffe A., Beran M., Blick M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem. 1989 Oct 5;264(28):16411–16420. [PubMed] [Google Scholar]
  26. Zwelling L. A., Slovak M. L., Doroshow J. H., Hinds M., Chan D., Parker E., Mayes J., Sie K. L., Meltzer P. S., Trent J. M. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II. J Natl Cancer Inst. 1990 Oct 3;82(19):1553–1561. doi: 10.1093/jnci/82.19.1553. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES